Oncolytics Biotech Inc T.ONC

CG Oncology

[lonc17]

CG Onoclogy raised almost $400 million U.S. and has a valuation of over $1 Billion U.S.

Oncolytics Biotech rasied $15 million U.S. (six months ago with the help of a predatory hedge fund that shorted shares ahead of the private placement and decimated shareholder value). Oncolytics Biotech has a valuation of under $100 Million U.S.

Here's the primary differences:

CG is currently enrolling patients in two different phase 3 trials (for bladder cancer).

ONC has talked about a phase 3 in breast cancer for the past five yeaas and has talked about a phase 3 in panc for more than one year. Neither have been submitted for registration with the FDA and ONC does not have the necessary capital to run on their own, neither do they have interest from big pharma. 

CG has a strong c-suite. 

ONC has Matt Coffey. 

CG has a clean track record of successful prior trials in one well focused indication.

ONC has a 25 year history of failed and marginal results in more than a dozen different cancers (brain, prostate, melanoma, head and neck, ovarian, etc., just think of any part of the body and they've shown pelareorep does not work) and ONC has also demonstrated that pelareorep is ineffective when combined with at least ten different drugs. ONC went so far as to "rebrand" their product and change the name (Reolysin became Pelareorep) so as to sweep twenty years of failed trial history under the rug and hope no one does their homework. 

CG is waiting for resutlts from their two phase 3 trials. 

ONC is waiting for the phone to ring, hoping like hell that a hail mary offer is on the line.

[inthno]

Irving, Calif.-based CG Oncology (CGON) offered 20 million shares at $19 as it raised $380 million with underwriters Morgan Stanley, Goldman Sachs and Cantor Fitzgerald. Including an additional three million shares to be sold by underwriters, the deal will raise $437 million.

[Azzak34]

Hey Deman, John Lennon died. 

[Noteable]

That notwithstanding, CG Oncology's oncolytic product CANNOT be delivered intravenously.

[Noteable]

So De_man,  now that you went off like a teenager having a wet dream, tell us how much it will cost CG Oncology to develop an intravenous (IV) delivered product?

[inthno]

Hey Noteable, I am not sure why you are attacking me, all I said was cg oncolodgy raised 437 million dollars and that was all, No comments or anything. So while we are at it, it would appear that the market seems to like cg oncology as they were able to raise more than 4 times what onc is worth. And btw, yes onc has 450 million in accumulated debt but you cannot just add that on to a BO price if

[Noteable]

De_man, you again have missed my point that while it took ONCY $450 million to develop an intravenously delivered OV, CG Oncology has yet to come to the point of having an IV product. Delivering a product intravessically (intratumorally) like CG Oncology is doing to treat superficial bladder cancer, is a completley different story than treating metastatic cancer which has become widespread and

[inthno]

Note, I was not comparing products, all I did was say that cg oncology raised 437 million dollars end of story, I did not care whether it was introvenus administration or not and it would appear that the market did not care either or they would not have been able to raise that much money and they are already in a phase 3 so someone believes in them to allow for such a big IPO. So what have we

[Noteable]

De_man - while you are so engaged in constantly whining about the past you keep missing the big picture going forward. And no - we are not going to go back and forth, as you keep trying to suggest. You have been proven wrong in each attempt that you've previously mounted  ... and that hasn't changed now either.  

[Normandt]

De_man message from stocktwits:  ""they enroll 116 patients in a monotherapy trial and onc enrolls 10-20 patients in multiple trials and says they have 2 phase 3 ready trials. We raise 20 million dollars U.S. with a hedge fund and they raise 487 million U.S. with multiple well known institutions.   And everyone thinks that we are worth billions. "" De_man

[Noteable]

Yeah - that De_man is a funny guy ... De_man is one who can't tell the difference between one of his confused posts and another of his many contortions.

[venture009]

From the very beginning ONC has always made a corporate decision to have small number of patients in their trials.  I follow ELVN and they have just announced 2 trials both with an excess of 100 patients. How can you ever say conclusively you have statistical significance with 10 to 15 patients.  What's the point.

[itntdf]

using fda approved surrogate endpoints.

[itntdf]

or more precisely, successfully using an approved fda surrogate enpoint, obtaining the marketing authorization which comes with a fast track approval, and then conducting a phase 4 post-marketing study to provide the fda with additional information including the treatment or drug's risks, benefits, and best use utilizing a medium to large size trial which in not randomized as opposed to

[Noteable]

Statistical significance is not a requirement with an Accelerated Approval. .... only the use of surrogate endpoints. Surrogate endpoints are used when the endpoint of interest is too difficult and/or expensive to measure routinely and when they can define some other, more readily measurable, endpoint, that is sufficiently well correlated with the first to justify its use as a substitute

[Normandt]

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation. Study Start (Actual)  2022-05-22 Primary Completion (Estimated)  2026-12 Study Completion (Estimated)  2026-12 Enrollment (Estimated) 120 patients Cohort 1 10

[CMHarring218431]

excellent find!

[Jf4270393]

Glad to see high patient population.

[lonc17]

CG is now trading.  IPO at $19, and trading on opening day above $30. Current market cap of CGON is above $1.5 BIllion U.S. Current market cap of ONCY is less than $100 Million U.S. Market values CGON at more than 15 times the value of ONCY. Even more telling, on a day when oncolytic viruses are in the spotlight and we have our first Oncoltyic Virus Unicorn, at a time when one might

[lonc17]

CG is now trading.  IPO at $19, and trading on opening day above $30. Current market cap of CGON is above $1.5 BIllion U.S. Current market cap of ONCY is less than $100 Million U.S. Market values CGON at more than 15 times the value of ONCY. Even more telling, on a day when oncolytic viruses are in the spotlight and we have our first Oncoltyic Virus Unicorn, at a time when one

[lonc17]

This post has been removed in accordance with Community Policy

[Jf4270393]

Well done pukester. Live life negatively and allways use the should and could have pose. LOL

[Noteable]

February 21, 2024 -  For comparison to ONCY's per share target range. CG Oncology has an average outperform rating and price target range of $42 to $86, according to analysts polled by Capital IQ. Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target On Tuesday, Morgan Stanley initiated coverage on CG Oncology (NASDAQ:CGON) with an

[Noteable]

  Cantor Fitzgerald has started coverage of newly public CG Oncology with an overweight rating and a price target for the stock at US $75.

[13X2413]

I knew it!!!  Notes reappears and gets active with unrelated posts, Azz gets invisible and stock starts its journey downwards. 

[Noteable]

And who said that ONCY's share price wasn't being manipulated !!

[13X2413]

Your outlandish theory not helping my trading account. Time to get back to reality and post things that are pertinent to the sad situation this company finds itself in. 

[Noteable]

Oh Yeah, ... now I know who said that ONCY's share price wasn't being manipulated. numbersxnumbers .. one of the same operatives that I had named beforehand.

[Azzak34]

Oh hey random name generator idiot. I don't view or post everyday, busy living life. Have a go at it and see if yours improves any.  As I've said over and over, I could care less what you clowns do to the stock price day to day. I'm here for the pay off and that'll be happening soon enough.  For people who hold stock and come here to complain everyday, you are as

[13X2413]

I prefer operative to idiot. It's so cute when you get angry. :)

[Noteable]

CG’s lead asset is an oncolytic virus immunotherapy, recently granted an Accelerated Approval for the intravesical infusion treatment of high-grade non-muscle invasive bladder cancer (NMIBC).   With intravesical therapy, the doctor puts a liquid drug right into the patient's bladder rather than giving it by mouth or injecting it into their blood. The drug is given through a tube